An absolute risk generalizable risk calculator is challenging. Led by So Mi Jemma Cho, evaluating AHA PREVENT across 4 academic health systems, we found similar discrimination but variable calibration. A universal absolute risk threshold may not suitably guide.

This autumn, we’re launching a new series of Advanced Courses on Non-classical risk factors for cardiovascular disease! If you're a clinician or healthcare practitioner and want to deepen your understanding of chronic inflammation, metabolic disturbances, gut microbiota,

This paper is so important and puts to rest those jumping on the VLDL/remnant bandwagon at the expense of ignoring LDLs. What everyone needs to do is order apoB, a one-time Lp(a) and then work hard at lowering apoB. The treatments that lower apoB lower both remnant-P and LDL-P

☝️No estimate of the apoB lipoprotein-related risk of CVD is complete without measurement of both apoB and Lp(a) ApoB is the true core marker of atherogenic particle burden, and Lp(a) is an independent, non-negotiable player in cardiovascular risk. ✅ ApoB reflects the number

Here the Sniderman editorial. Digest it slowly, one sentence at a time. It is so rich in facts.

TG Takeover: Rapid-Fire Updates on Advances in sHTG and FCS x.com/i/broadcasts/1…

Interesting in looking at markers other than CRP.

🔬@lipidjournal #ScienceSpotlight: New study links lower LDL-C & Lp(a) with smaller lipid core plaques and reduced atherosclerotic vulnerability. Could Lp(a) targeting further stabilize coronary atheroma? 🧠Read more: ow.ly/B2u350WsJVO

Congratulations Sek on such an amazing achievement! Looking forward to seeing how your science will translate to clinical care.

How would ASCVD change if apiB was treated like BP from an early age?

academic.oup.com/eurheartj/adva…

Very very promising news!

Spotty calcification is positively associated with features of plaque vulnerability, such as lipid-rich plaque and macrophage 🔗atherosclerosis-journal.com/article/S0021-… European Atherosclerosis Society #EASSoMe

David H. Wiener, MD Prof Derek Connolly Vincenzo De Sio Salvatore De Rosa Dr. Fausto Heredia V FSIAC Dr Anastasia Mihailidou FAHA FCSANZ FESC Giuseppe Maltese John P Erwin III MD MBA MACC (#BigPoppy ) Ezequiel Zaidel Ezequiel Forte Seba GZ, MD, MSc Adrian Baranchuk MD FACC FRCPC FCCS FSIAC Mamas A. Mamas Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 Stefano Cacciatore, MD Marta Kaluzna-Oleksy Michał Chudzik Michele Marchetta Roger Blumenthal Ritu Thamman MD Nicolas Renna, MD PhD ISHF FESC

In data from the UK Biobank, higher Lp(a) concentrations were associated with incident extracoronary atherosclerotic vascular disease (both peripheral arterial disease & carotid artery stenosis) and progression to major adverse limb events or stroke. ahajournals.org/doi/full/10.11…

🎯 Precision Lipidology Enters the RNA Era Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are reshaping lipid management by targeting mRNA degradation at the source. 👉Inclisiran targets PCSK9 → ↓LDL-C 👉Volanesorsen, Olezarsen, Plozasiran target

Lp(a) as a Prognostic Marker of ASCVD Progression New study with 460k participants showed that: 1️⃣ Median Lp(a) Levels: 1) No Vascular Disease: 19.5 nmol/L 2) Incident PAD: 25.3 nmol/L 3) PAD to MALE: 33.3 nmol/L 4) Incident Carotid Stenosis: 29.5 nmol/L 5) Carotid Stenosis to

Nice new article on the impaired lipid transport characteristic of APOE4 carriers Thomas Dayspring Austin Dudzinski, PharmD, BCACP Ethan J. Weiss John Kastelein Dr Scott W Murray LipoFan x jlr.org/article/S0022-…

Josh Austin Dudzinski, PharmD, BCACP Ethan J. Weiss John Kastelein Dr Scott W Murray LipoFan Thus could set the stage for apoA-I to enter cross BBB, enter the matrisome and rescue dysfunctional apoE4-HDLs.

We have now developed methods to measure OxPL on most lipoproteins, in addition to Sam Tsimikas and OxPL-apo(a). One applications is in ALS (Lou Gehrig's disease), with OxPL-apoE being most interesting. Of course, this also has treatment implications by overexpressing OxPL